1589 Single-cell RNA sequencing analysis of human psoriatic skin with SLE treated with IL23 blockade

Systemic lupus erythematosus (SLE) and psoriasis are both chronic immune-mediated diseases. SLE is caused by T-helper 1 (Th1), Th2, Th17, B cell axis activation, while primarily driven Th17 activation. Coexistent has been reported. A phase II trial of patients with active demonstrated that ustekinumab (interleukin (IL)12 23 blockade) resulted in significant Responder Index improvement when added to standard therapy. However, exacerbation or new onset a patient concomitant also reported after anti-IL17/IL23 antibody treatment, suggesting the complexity disease pathogenesis. Herein, we report 42-year-old male 7-year history 16-year psoriasis. Although his activity was stable, guselkumab (IL23 inhibitor) given for treatment severe To characterize skin changes following IL23 blockade, performed single-cell RNA sequencing T-cell receptor clonal analyses comparing non-lesional, lesional, post-treatment lesional skin. We observed several frequency populations together multiple transcriptomics changes.